H.C.WAINWRIGHT&CO.

Company Update
Healthcare
January 29, 2026

OKYO Pharma Limited (OKYO)
Rating: Buy

Yi Chen, Ph.D. CFA
212-916-3971
ychen@hcwresearch.com
Raghuram Selvaraju, Ph.D.
212-916-3966
rselvaraju@hcwresearch.com

FDA Endorses Planned Phase 2b/3 Trial in Neuropathic Corneal Pain; Reiterate Buy

Stock Data	1/28/2026
Price	$2.19
Exchange	NASDAQ
Price Target	$7.00
52-Week High	$3.35
52-Week Low	$0.90
Enterprise Value (M)	$78
Market Cap (M)	$82
Shares Outstanding (M)	37.6
3 Month Avg Volume	186,420
Short Interest (M)	0.16
Balance Sheet Metrics	
Cash (M)	$4.3
Total Debt (M)	$0.0
Total Cash/Share	$0.11
Book Value/Share	$(0.08)

Cash (M): pro forma

EPS ($) Diluted			
Full Year - Mar	2024A	2025A	2026E
1Q	--	--	(0.02)
2Q	(0.34)	(0.08)	(0.02)
3Q	--	--	(0.05)
4Q	(0.24)	(0.06)	(0.08)
FY	(0.50)	(0.12)	(0.19)

Revenue ($M)			
Full Year - Mar	2024A	2025A	2026E
1Q	--	--	0.0
2Q	0.0	0.0	0.0
3Q	--	--	0.0
4Q	0.0	0.0	0.0
FY	0.0	0.0	0.0

OKYO reports semiannually. Our projections are offered quarterly.



FDA confirms Phase 2b/3 trial design; study slated to start in 1H26. Yesterday, OKYO Pharma announced that it had a successful Type C meeting with the FDA regarding the Phase 2b/3 trial of urcosimod for the treatment of neuropathic corneal pain (NCP). Key highlights from the meeting include (1) FDA confirmed the approach that the proposed primary endpoint of the Visual Analogue Scale (VAS) pain reduction at Week 12 is clinically meaningful, including explicit acknowledgment that a ≥2-point improvement on the VAS scale represents a meaningful treatment effect; (2) FDA provided statistical guidance to enhance robustness; (3) FDA endorsed the proposed study design, sample size (n=120), and powering assumptions, and agreed that the Ocular Pain Assessment Survey (OPAS) is appropriate as supportive quality-of-life evidence; and (4) FDA alignment on the Chemistry, Manufacturing and Controls (CMC) strategy and key clinical elements, with no material issues raised. With the FDA's endorsement, the company is slated to initiate the Phase 2b/3 trial in 1H26. We reiterate our Buy rating and $7 PT.

Favorable changes in corneal nerve structure observed in the neuropathic corneal pain trial. In December 2025, OKYO Pharma announced favorable data from new analyses based on corneal images from the Phase 2 trial of urcosimod in neuropathic corneal pain (NCP) (n=18). The analyses showed that patients treated with 0.05% urcosimod demonstrated favorable changes in corneal nerve structure, which were not observed in the placebo group. Specifically, the urcosimod group showed median increases in total nerve fiber count (+2.0, n/0.16 mm², Inter Quartile Range (IQR) 0.54 to 3.63) and total nerve fiber length (+2.6 mm/mm², IQR 1.55 to 5.67; p=0.057 vs. placebo). In comparison, the placebo group showed median decreases in total nerve fiber count (-1.92, n/0.16 mm², IQR -2.79 to -0.04) and total nerve fiber length (-1.63 mm/mm², IQR -3.76 to 0.63). While this is an exploratory endpoint, the consistent and meaningful directional improvements demonstrate the potential of urcosimod to support corneal nerve restoration, in our view. Combined neuropathic corneal pain with previously announced data showing statistically significant reduction in mean pain scores, the improvements in corneal nerve structure suggest that targeting the chemerin receptor pathway could be a viable therapeutic approach for NCP, which has no FDA-approved therapy.

Phase 2 data show statistically significant pain reduction in NCP. In July 2025, the company reported positive proof-of-concept data from a Phase 2 trial of urcosimod for the treatment of NCP. This double-masked, randomized, placebo-controlled study enrolled 18 patients at a single site and 17 patients have completed the study. Subjects were randomized in a 1:1:1 ratio to receive treatment with 0.05% urcosimod, or 0.1% urcosimod, or placebo four times daily for 12 weeks. The primary endpoint is change in mean pain scores from baseline (Visit 1, Day 0) to end of treatment (Visit 4, Day 84) as measured by a VAS score (on 0-10 scale where 0 is no pain and 10 is worst pain imaginable). Results showed that the 0.05% urcosimod group had a statistically significant reduction in mean pain scores of 5.5 (p=0.025), while the placebo group had a reduction in mean pain scores of 2.75 (p=0.035), thus demonstrating a delta of 2.75 between urcosimod and placebo following the 12-week treatment period. Of note, all the patients in the 0.05% urcosimod group had moderate to severe NCP pain scores, while 75% of placebo group patients had only mild NCP pain scores at baseline, indicating a worse baseline condition for the 0.05% urcosimod group. In addition, 67% of patients in the 0.05% urcosimod group demonstrated greater than 50% improvement in pain compared to 33% in the placebo group, and 0.05% urcosimod showed a marked reduction in pain scores as early as Week 4.

Valuation and Risks. Our 12-month price target is derived from an estimated market value of the firm at $300M. This includes a discounted cash flow (DCF) analysis-based asset value of $300M for urcosimod (formerly OK-101), using a 15% discount rate and 1% terminal growth rate, and conservatively excludes the cash position. Assigned probability of approval is 15% for DED and 20% for NCP. Assuming 43M shares outstanding at the end of September 2026, this yields a value of approximately $7 per share. Risks include, but are not limited to: (1) failure of urcosimod in clinical trials; (2) failure of urcosimod to secure regulatory approval in the U.S.; (3) failure of urcosimod to achieve commercial success due to market size, penetration rate, and/or competition; and (4) dilution risk.

Table 1: OKYO Pharma Limited (OKYO)—Historical Income Statements, Financial Projections

FY end March 31
$ in thousands, except per share data

			2025A			2026E					
	2023A	2024A	1HA	2HA	2025A	1Q	2Q	3Q	4Q	2026E
Revenue											
Product revenue	-	-			-						-
Other revenue	-	-			-						-
Total revenue	-	-	- -	- -	-	-	-	-	-	-	-
Expenses											
Cost of sales	-	-	-	- -	-	-	-	-	-	-	-
Research and development	6,338	8,244	2,216	38	2,254	50	50	1,000	2,000	3,100	
General and administrative	6,850	7,506	1,123	3,714	4,838	800	800	1,200	1,500	4,300	
Total expenses	13,187	15,750	- 3,339	- 3,753	7,092	850	850	2,200	3,500	7,400	
Gain (loss) from operations	(13,187)	(15,750)	- (3,339)	- (3,753)	(7,092)	(850)	(850)	(2,200)	(3,500)	(7,400)	
Other income/expense											
Finance costs	(97)	(1,053)	(758)	(120)	(878)						-
Finance income	-	-			-						-
Total investment income and other	(97)	(1,053)	- (758)	- (120)	(878)	-	-	-	-	-	
Loss before provision for income taxes	(13,284)	(16,803)	- (4,098)	- (3,872)	(7,970)	(850)	(850)	(2,200)	(3,500)	(7,400)	
Provision for income taxes	12	(22)	1,418	1,846	3,264						-
Net income (loss)	(13,272)	(16,825)	- (2,680)	- (2,026)	(4,706)	(850)	(850)	(2,200)	(3,500)	(7,400)	
Net loss per share (basic)	(0.60)	(0.50)	(0.08)	(0.06)	(0.12)	(0.02)	(0.02)	(0.05)	(0.08)	(0.19)	
Net loss per share (diluted)	(0.60)	(0.50)	(0.08)	(0.06)	(0.12)	(0.02)	(0.02)	(0.05)	(0.08)	(0.19)	
Weighted average number of shares outstanding (basic)	22,257	33,336	33,573	36,021	39,488	36,816	37,618	40,133	42,648	39,304	
Weighted average number of shares outstanding (diluted)	22,257	33,336	33,573	36,021	39,488	36,816	37,618	40,133	42,648	39,304	

Source: Company reports and H.C. Wainwright & Co. estimates.

Table 2: OKYO Pharma Limited (OKYO)—Historical Balance Sheets, Financial Projections

FY end March 31
$ in thousands, except per share data

			2025A			2026E					
	3/31/2023	3/31/2024	9/30/2024	3/31/2025	3/31/2025	6/30/2025	9/30/2025	12/31/2025	3/31/2026	3/31/2026
Assets										
Current assets:										
Cash and cash equivalents	4,045	827	987	1,561	1,561	3,646	2,996	10,296	6,996	6,996
Related party receivables		-			-	-	-	-	-	-
Current taxation receivable	559	559	1,483	1,872	1,872	1,872	1,872	1,872	1,872	1,872
Other receivables	592	152	356	242	242	242	242	242	242	242
Total current assets	5,197	1,538	- 2,827	- 3,675	3,675	5,761	5,111	12,411	9,111	9,111
Property and Equipment, net	7	3	2	2	2	2	2	2	2	2
Right of use asset		-			-	-	-	-	-	-
Total Assets	5,204	1,541	- 2,829	- 3,677	3,677	5,763	5,113	12,413	9,113	9,113
Liabilities and shareholder equity										
Current liabilities										
Trade and other payables	4,263	7,062	9,607	8,368	8,368	8,368	8,368	8,368	8,368	8,368
Related party payable	779	359	446	859	859	859	859	859	859	859
Loan payable to related party	2,215	-	2		-	-	-	-	-	-
Lease liabilities - current		-			-	-	-	-	-	-
Total current liabilities	7,257	7,421	- 10,054	- 9,227	9,227	9,227	9,227	9,227	9,227	9,227
Lease liabilities - non current	-	-	-	- -	-	-	-	-	-	-
Total Liabilities	7,257	7,421	- 10,054	- 9,227	9,227	9,227	9,227	9,227	9,227	9,227
Shareholder's equity										
Ordinary share capital		-			-	-	-	-	-	-
Share premium	131,386	143,113	144,050	146,717	146,717	149,453	149,453	158,753	158,753	158,753
Accumulated dificit	(125,698)	(142,523)	(145,203)	(143,025)	(143,025)	(143,675)	(144,325)	(146,325)	(149,625)	(149,625)
Share options reserve	3,629	4,749	5,075	1,185	1,185	1,185	1,185	1,185	1,185	1,185
Warrants reserve	82	94	94	94	94	94	94	94	94	94
Shares to be issued (Loan Notes) - Equity		-	115		-	-	-	-	-	-
Convertible Loan Note reserve		-	435	950	950	950	950	950	950	950
Foreign currency translation reserve	(11,453)	(11,311)	(11,792)	(11,470)	(11,470)	(11,470)	(11,470)	(11,470)	(11,470)	(11,470)
Total stockholders' equity	(2,053)	(5,880)	- (7,226)	- (5,550)	(5,550)	(3,464)	(4,114)	3,186	(114)	(114)
Total liability and shareholder's equity	5,204	1,541	- 2,829	- 3,677	3,677	5,763	5,113	12,413	9,113	9,113

Source: Company reports and H.C. Wainwright & Co. estimates.

Important Disclaimers

This material is confidential and intended for use by Institutional Accounts as defined in FINRA Rule 4512(c). It may also be privileged or otherwise protected by work product immunity or other legal rules. If you have received it by mistake, please let us know by e-mail reply to unsubscribe@hcwresearch.com and delete it from your system; you may not copy this message or disclose its contents to anyone. The integrity and security of this message cannot be guaranteed on the Internet.

H.C. WAINWRIGHT & CO, LLC RATING SYSTEM: H.C. Wainwright employs a three tier rating system for evaluating both the potential return and risk associated with owning common equity shares of rated firms. The expected return of any given equity is measured on a RELATIVE basis of other companies in the same sector. The price objective is calculated to estimate the potential movements in price that a given equity could reach provided certain targets are met over a defined time horizon. Price objectives are subject to external factors including industry events and market volatility.

RETURN ASSESSMENT

Market Outperform (Buy): The common stock of the company is expected to outperform a passive index comprised of all the common stock of companies within the same sector.

Market Perform (Neutral): The common stock of the company is expected to mimic the performance of a passive index comprised of all the common stock of companies within the same sector.

Market Underperform (Sell): The common stock of the company is expected to underperform a passive index comprised of all the common stock of companies within the same sector.

Investment Banking Services include, but are not limited to, acting as a manager/co-manager in the underwriting or placement of securities, acting as financial advisor, and/or providing corporate finance or capital markets-related services to a company or one of its affiliates or subsidiaries within the past 12 months.

Distribution of Ratings Table as of January 27, 2026

			IB Service/Past 12 Months	
Ratings	Count	Percent	Count	Percent
Buy	576	87.27%	146	25.35%
Neutral	59	8.94%	8	13.56%
Sell	1	0.15%	0	0.00%
Under Review	24	3.64%	4	16.67%

H.C. Wainwright & Co, LLC (the “Firm”) is a member of FINRA and SIPC and a registered U.S. Broker-Dealer.

I, Yi Chen, Ph.D. CFA and Raghuram Selvaraju, Ph.D. , certify that 1) all of the views expressed in this report accurately reflect my personal views about any and all subject securities or issuers discussed; and 2) no part of my compensation was, is, or will be directly or indirectly related to the specific recommendation or views expressed in this research report; and 3) neither myself nor any members of my household is an officer, director or advisory board member of these companies.

None of the research analysts or the research analyst’s household has a financial interest in the securities of OKYO Pharma Limited (including, without limitation, any option, right, warrant, future, long or short position).

As of December 31, 2025 neither the Firm nor its affiliates beneficially own 1% or more of any class of common equity securities of OKYO Pharma Limited.

Neither the research analyst nor the Firm knows or has reason to know of any other material conflict of interest at the time of publication of this research report.

The research analyst principally responsible for preparation of the report does not receive compensation that is based upon any specific investment banking services or transaction but is compensated based on factors including total revenue and profitability of the Firm, a substantial portion of which is derived from investment banking services.

The Firm or its affiliates did not receive compensation from OKYO Pharma Limited for investment banking services within twelve months before, but will seek compensation from the companies mentioned in this report for investment banking services within three months following publication of the research report.

The Firm does not make a market in OKYO Pharma Limited as of the date of this research report.

The securities of the company discussed in this report may be unsuitable for investors depending on their specific investment objectives and financial position. Past performance is no guarantee of future results. This report is offered for informational purposes only, and does not constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such would be prohibited. This research report is not intended to provide tax advice or to be used to provide tax advice to any person. Electronic versions of H.C. Wainwright & Co., LLC research reports are made available to all clients simultaneously. No part of this report may be reproduced in any form without the expressed permission of H.C. Wainwright & Co., LLC. Additional information available upon request.

H.C. Wainwright & Co., LLC does not provide individually tailored investment advice in research reports. This research report is not intended to provide personal investment advice and it does not take into account the specific investment objectives, financial situation and the particular needs of any specific person. Investors should seek financial advice regarding the appropriateness of investing in financial instruments and implementing investment strategies discussed or recommended in this research report.

H.C. Wainwright & Co., LLC's and its affiliates' salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies that reflect opinions that are contrary to the opinions expressed in this research report.

H.C. Wainwright & Co., LLC and its affiliates, officers, directors, and employees, excluding its analysts, will from time to time have long or short positions in, act as principal in, and buy or sell, the securities or derivatives (including options and warrants) thereof of covered companies referred to in this research report.

The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data on the company, industry or security discussed in the report. All opinions and estimates included in this report constitute the analyst's judgment as of the date of this report and are subject to change without notice.

Securities and other financial instruments discussed in this research report: may lose value; are not insured by the Federal Deposit Insurance Corporation; and are subject to investment risks, including possible loss of the principal amount invested.